Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Growing
The company is in a growing phase, with the latest annual income totaling USD 22.29M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 22.29M.
Fairly Valued
The company’s latest PE is -28.30, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 52.61M shares, decreasing 18.10% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 24.12K shares of this stock.